[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643744":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":19,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Genethon","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Cohort of 450 patients with neuro-muscular disease for AAV sero-analysis",null,[12],"Diagnostic Test: Dosage of AAV neutralizing antibodies",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Dosage of AAV neutralizing antibodies","In each clinical site, the principal investigator will propose to his patients with neuromuscular disease of genetic origin to take a blood sample (4 mL of blood) to determine their level of immunity to certain AAVs used in gene therapy. The collected samples will be prepared and aliquoted on site and then sent frozen to the GENETHON laboratory for analysis.\n\nOnly one sample per patient will be analyzed. All samples will be analyzed in batches.",[9],[20],{"facility":21,"status":10,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"GENETHON","Évry","Île-de-France Region","9100","France","FR",{"type":28,"coordinates":29},"Point",[30,31],2.44049,48.6328,{"lat":31,"lon":30},[34,39],{"name":35,"role":36,"phone":10,"phoneExt":37,"email":38},"Philippe VERON, Master of Sciences","CONTACT","+33","veron@genethon.fr",{"name":40,"role":36,"phone":10,"phoneExt":37,"email":41},"Céline LABETOULE, Master of Sciences","clabetoule@genethon.fr",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100643744","multicenter-epidemiological-study-for-the-evaluation-of-the-seroprevalence-of-total-and-neutralizing-antibodies-against-adenoassociated-virus-serotypes-used-in-gene-therapy-in-patients-with-neuromuscular-diseases-of-genetic-origin-100643744",false,"NCT07633951","Multicenter Epidemiological Study for the Evaluation of the Seroprevalence of Total and Neutralizing Antibodies Against Adenoassociated Virus Serotypes Used in Gene Therapy in Patients With Neuromuscular Diseases of Genetic Origin.","SeroDysMyo","Inclusion Criteria:\n\n1. Pediatric patient 6 years of age or older or adult under 60 years of age with genetic neuromuscular disease\n2. Informed patient who signed informed consent\n3. No opposition from the holders of parental authority or guardian, for minor patients.\n4. Affiliated\u002Fbeneficiary of a national health insurance scheme\n\nExclusion Criteria:\n\n* Gene or cell therapy treatment prior to blood collection","ALL","6 Years","60 Years",{"count":55,"type":56},450,"ESTIMATED","INTERVENTIONAL",[59],"NA","This study aims to assess the overall seroprevalence of neutralizing antibodies against different AAVs potentially used in gene therapy in patients with genetic neuromuscular diseases.",[62,63],"Neuromuscular Deficits","Genetic Disorder",[65,66,67,68,69,70],"AAV","Seroprevalence","Nab","Tab","neuromuscular","Genetic disorder","NOT_YET_RECRUITING","2026-06-03",{"date":74,"type":75},"2026-06-08","ACTUAL",{"date":77,"type":56},"2026-07-31",{"date":79,"type":56},"2027-12-31",{"name":5,"class":6},1]